Effect of magnesium sulfate in patients with preeclampsia with severe features on gastric antrum cross-sectional area: a prospective observational study
Authors' conclusion
In patients with preeclampsia with severe features, magnesium sulfate 5 g is associated with a significant increase in gastric antrum CSA.
Study context
- Population
- Patients with preeclampsia with severe features receiving IV magnesium sulfate 5 g over 20 min, then 1 g/h infusion
- Participants
- 31 patients
- Exposure
- 20 min vs Baseline
- Outcome
- Change in gastric antrum CSA (gastric ultrasound)
- Follow-up
- 20 min post-bolus
Main finding
As reported in the abstract
Gastric antrum CSA
P < 0.001
Observational data: associations, not effects.
Secondary outcomes
- Unsafe gastric volume (cross-sectional area (CSA) > 608 mm²) — Baseline
- 2 events
- Unsafe gastric volume (CSA > 608 mm²): 10 min post-bolus 5 events
- Unsafe gastric volume (CSA > 608 mm²): 20 min post-bolus 7 events
- Unsafe gastric volume (CSA > 608 mm²): of 31 participants
Serum magnesium levels
- Serum magnesium increased from 1.96 ± 0.26 mg/dL to 5.24 ± 0.86 mg/dL (mean difference 3.27 ± 0.80 mg/dL)
Correlation between change in serum magnesium and change in CSA
- Strong positive correlation (r)
- +0.896
- P < 0.001
Original publication
Effect of magnesium sulfate in patients with preeclampsia with severe features on gastric antrum cross-sectional area: a prospective observational study. Int J Obstet Anesth. Published 10 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →